While the report does not claim to be a "cookbook," it provides an essential framework for developing scientifically sound LER hold-time studies and has been recognized by major health authorities—including the FDA and EMA—as a relevant standard. Since its publication in 2019, industry experience has validated many of its recommendations while also identifying areas requiring revision, leading to the current update effort that will ensure PDA TR 82 continues to serve as an indispensable resource for years to come.
Discovered in 2013, LER occurs when a known amount of bacterial endotoxin is spiked into an undiluted drug product but cannot be recovered during subsequent testing. The Technical Definition
To prove that a drug product does not mask endotoxins, manufacturers must perform hold studies as part of their analytical method validation. TR 82 outlines the best practices for executing these studies:
Adding specific agents that reverse the masking of the endotoxin micelle.
Utilizing specific sample treatments, such as surfactants or dispersants, designed to break up the aggregated endotoxin and make it detectable. pda technical report 82
TR 82 emphasizes that every pharmaceutical manufacturer, particularly those producing biologics with chelators and surfactants, must evaluate their product for LER. The report outlines best practices for designing these studies: A. Endotoxin Source and Spiking
: It included 12 real-world industry case studies, which make up the bulk of the report, to show how different labs successfully tackled the problem.
Review all marketed and pipeline parenteral products. Flag any containing polysorbates (20 or 80), Cremophor, cyclodextrins, or EDTA.
The report includes anonymized real-world data, such as: While the report does not claim to be
PDA TR 82 fundamentally changed the paradigm from "Does the test pass?" to "Does the test remain valid throughout the shelf-life of the sample?"
The differences between spikes in validation testing. Share public link
The PDA Technical Glossary, referencing TR 82, formally defines Low Endotoxin Recovery as "the inability to recover ≥50% activity over time when a known amount of endotoxin is added to an undiluted product." It further notes that LER cannot be overcome by simply diluting the product. In simpler terms, if you add a known quantity of endotoxin to a drug formulation and measure it over time, a standard BET might only detect less than half of it, giving a false sense of security.
Per the guidelines in PDA TR 82, LER is formally identified when an undiluted product sample fails to achieve ≥is greater than or equal to The Technical Definition To prove that a drug
Throughout the early 2010s, regulatory authorities (FDA, EMA) and industry leaders noticed an increase in OOS (Out of Specification) investigations related to unexpected negative endotoxin results. The scientific community realized that the standard BET was being "fooled" by modern biopharmaceutical formulations—particularly those containing polysorbates (Tween 80, Tween 20) and chelating agents like EDTA.
Providing actionable steps to overcome LER during testing.
Overall, the PDA Technical Report 82 is a critical guideline that provides comprehensive recommendations for the manufacture, testing, and control of parenteral drug products. Its implementation can bring significant benefits, including improved product quality, reduced risk, and enhanced regulatory compliance.
As of 2026, regulatory agencies like the FDA and EMA encourage a risk-based approach to LER.
The PDA Technical Report 82 is a valuable resource for pharmaceutical and biotechnology companies, regulatory agencies, and industry professionals involved in the development, production, and quality control of parenteral drug products. By following the guideline's recommendations, manufacturers can ensure that their products meet quality standards, are safe for use, and comply with regulatory requirements. As the pharmaceutical and biotechnology industries continue to evolve, the PDA Technical Report 82 will remain a critical tool for ensuring the quality and safety of parenteral drug products.